The genetics of clinical outcome in multiple sclerosis

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 183-199

  Ramagopalan, Sreeram V ^a,b   DeLuca, Gabriele C ^a,b   Degenhardt, Alexandra ^b   Ebers, George C ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Genetics; Multiple sclerosis; Outcome

Indexed keywords

APOLIPOPROTEIN E; CD24 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR 1; HLA ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MYELOPEROXIDASE; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CLONAL ANERGY; DOWN REGULATION; GENE INTERACTION; GENOTYPE; HUMAN; IMMUNOREGULATION; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION;

ANIMALS; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; LINKAGE (GENETICS); MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; RECEPTORS, ESTROGEN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 51649096593     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.02.016     Document Type: Article

References (188)

1. Al-Shammri S., Fatania H., Al-Radwan R., and Akanji A.O. The relationship of APOE genetic polymorphism with susceptibility to multiple sclerosis and its clinical phenotypes in Kuwaiti Arab subjects. Clin. Chim. Acta 351 (2005) 203-207
2. Almeras L., Meresse B., Seze J., De Lefranc D., Dubucquoi S., Fajardy I., Vermersch P., and Prin L. Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. Eur. Cytokine Netw. 13 (2002) 200-206
3. Bai X.F., Liu J.Q., Liu X., Guo Y., Cox K., Wen J., Zheng P., and Liu Y. The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. J. Clin. Invest. 105 (2000) 1227-1232
4. Bai X.F., Li O., Zhou Q., Zhang H., Joshi P.S., Zheng X., Liu Y., Wang Y., Zheng P., and Liu Y. CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J. Exp. Med. 200 (2004) 447-458
5. Ballerini C., Campani D., Rombola G., Gran B., Nacmias B., Amato M.P., Siracusa G., Bartolozzi L., Sorbi S., and Massacesi L. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci. Lett. 296 (2000) 174-176
6. Ballerini C., Guerini F.R., Rombola G., Rosati E., Massacesi L., Ferrante P., Caputo D., Talamanca L.F., Naldi P., Liguori M., Alizadeh M., Momigliano-Richiardi P., and D'Alfonso S. HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe. J. Neuroimmunol. 150 (2004) 178-185
7. Barcellos L.F., Oksenberg J.R., Green A.J., Bucher P., Rimmler J.B., Schmidt S., Garcia M.E., Lincoln R.R., Pericak-Vance M.A., Haines J.L., and Hauser S.L. Genetic basis for clinical expression in multiple sclerosis. Brain 125 (2002) 150-158
8. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., Goodin D.S., Pelletier D., Lincoln R.R., Bucher P., Swerdlin A., Pericak-Vance M.A., Haines J.L., and Hauser S.L. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72 (2003) 710-716
9. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., Cree B.C., Begovich A.B., Villoslada P., Montalban X., Uccelli A., Savettieri G., Lincoln R.R., DeLoa C., Haines J.L., Pericak-Vance M.A., Compston A., Hauser S.L., and Oksenberg J.R. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 15 (2006) 2813-2824
10. Berr C., Dugoujon J.M., Clanet M., Cambon-Thomsen A., and Alperovitch A. A possible new genetic marker associated with a severe course of multiple sclerosis, located on chromosome 2: Km. N. Engl. J. Med. 320 (1989) 467
11. Bertrams J., Hoher P.G., and Kuwert E. Letter: HL-A antigens in multiple sclerosis. Lancet 1 (1974) 1287
12. Bettelli E., Das M.P., Howard E.D., Weiner H.L., Sobel R.A., and Kuchroo V.K. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161 (1998) 3299-3306
13. Bilinska M., Frydecka I., Noga L., Dobosz T., Zoledziewska M., Suwalska K., Tutak A., and Pokryszko-Dragan A. Progression of multiple sclerosis is associated with exon 1 CTLA-4 gene polymorphism. Acta Neurol. Scand. 110 (2004) 67-71
14. Brassat D., Azais-Vuillemin C., Yaouanq J., Semana G., Reboul J., Cournu I., Mertens C., Edan G., Lyon-Caen O., Clanet M., Fontaine B., and French Multiple Sclerosis Genetics Group. Familial factors influence disability in MS multiplex families. Neurology 52 (1999) 1632-1636
15. Braun N., Michel U., Ernst B.P., Metzner R., Bitsch A., Weber F., and Rieckmann P. Gene polymorphism at position-308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci. Lett. 215 (1996) 75-78
16. Brennan M., Gaur A., Pahuja A., Lusis A.J., and Reynolds W.F. Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis. J. Neuroimmunol. 112 (2001) 97-105
17. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. J. Neurol. Neurosurg. Psychiatry 51 (1988) 412-415
18. Bulman D.E., Sadovnick A.D., and Ebers G.C. Age of onset in siblings concordant for multiple sclerosis. Brain 114 Pt 2 (1991) 937-950
19. Burwick R.M., Ramsay P.P., Haines J.L., Hauser S.L., Oksenberg J.R., Pericak-Vance M.A., Schmidt S., Compston A., Sawcer S., Cittadella R., Savettieri G., Quattrone A., Polman C.H., Uitdehaag B.M., Zwemmer J.N., Hawkins C.P., Ollier W.E., Weatherby S., Enzinger C., Fazekas F., Schmidt H., Schmidt R., Hillert J., Masterman T., Hogh P., Niino M., Kikuchi S., Maciel P., Santos M., Rio M.E., Kwiecinski H., Zakrzewska-Pniewska B., Evangelou N., Palace J., and Barcellos L.F. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 66 (2006) 1373-1383
20. Caillier S., Barcellos L.F., Baranzini S.E., Swerdlin A., Lincoln R.R., Steinman L., Martin E., Haines J.L., Pericak-Vance M., Hauser S.L., and Oksenberg J.R. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun. 4 (2003) 312-315
21. Cardon L.R., and Abecasis G.R. Using haplotype blocks to map human complex trait loci. Trends Genet. 19 (2003) 135-140
22. Celius E.G., Harbo H.F., Egeland T., Vartdal F., Vandvik B., and Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J. Neurol. Sci. 178 (2000) 132-135
23. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., and Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294 (2001) 1731-1735
24. Chapman J., Sylantiev C., Nisipeanu P., and Korczyn A.D. Preliminary observations on APOE epsilon4 allele and progression of disability in multiple sclerosis. Arch. Neurol. 56 (1999) 1484-1487
25. Chapman J., Vinokurov S., Achiron A., Karussis D.M., Mitosek-Szewczyk K., Birnbaum M., Michaelson D.M., and Korczyn A.D. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 56 (2001) 312-316
26. Chataway J., Mander A., Robertson N., Sawcer S., Deans J., Fraser M., Broadley S., Clayton D., and Compston A. Multiple sclerosis in sibling pairs: an analysis of 250 families. J. Neurol. Neurosurg. Psychiatry 71 (2001) 757-761
27. Chiocchetti A., Comi C., Indelicato M., Castelli L., Mesturini R., Bensi T., Mazzarino M.C., Giordano M., D'Alfonso S., Momigliano-Richiardi P., Liguori M., Zorzon M., Amoroso A., Trojano M., Monaco F., Leone M., Magnani C., and Dianzani U. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J. Neuroimmunol. 163 (2005) 172-178
28. Cocco E., Sotgiu A., Costa G., Murru M.R., Mancosu C., Murru R., Lai M., Contu P., and Marrosu M.G. HLA-DR,DQ and APOE genotypes and gender influence in Sardinian primary progressive MS. Neurology 64 (2005) 564-566
29. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T., and Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med. 339 (1998) 285-291
30. Davie C.A., Barker G.J., Webb S., Tofts P.S., Thompson A.J., Harding A.E., McDonald W.I., and Miller D.H. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118 Pt 6 (1995) 1583-1592
31. de Jong B.A., Schrijver H.M., Huizinga T.W., Bollen E.L., Polman C.H., Uitdehaag B.M., Kersbergen M.C., Sturk A., and Westendorp R.G. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann. Neurol. 48 (2000) 641-646
32. de Jong B.A., Westendorp R.G., Eskdale J., Uitdehaag B.M., and Huizinga T.W. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum. Immunol. 63 (2002) 281-285
33. *1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J. Neuroimmunol. 80 (1997) 172-178
34. Dejaegher L., de Bruyere M., Ketelaer P., and Carton H. HLA antigens and progression of multiple sclerosis. Part II. J. Neurol. 229 (1983) 167-174
35. DeLuca G.C., Ebers G.C., and Esiri M.M. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 127 (2004) 1009-1018
36. DeLuca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., Pugliatti M., Barnardo M.C., Risch N.J., Sadovnick A.D., Chao M., Sotgiu S., Hudson T.J., and Ebers G.C. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20896-20901
37. Diab A., Zhu J., Xiao B.G., Mustafa M., and Link H. High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J. Neuropathol. Exp. Neurol. 56 (1997) 641-650
38. Dincic E., Zivkovic M., Stankovic A., Obradovic D., Alavantic D., Kostic V., and Raicevic R. Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J. Neuroimmunol. 177 (2006) 146-150
39. Drulovic J., Popadic D., Mesaros S., Dujmovic I., Cvetkovic I., Miljkovic D., Stojsavljevic N., Pravica V., Pekmezovic T., Bogdanovic G., Jarebinski M., and Mostarica Stojkovic M. Decreased frequency of the tumor necrosis factor alpha -308 allele in Serbian patients with multiple sclerosis. Eur. Neurol. 50 (2003) 25-29
40. Drysdale C.M., McGraw D.W., Stack C.B., Stephens J.C., Judson R.S., Nandabalan K., Arnold K., Ruano G., and Liggett S.B. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10483-10488
41. Duquette P., Decary F., Pleines J., Boivin D., Lamoureux G., Cosgrove J.B., and Lapierre Y. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can. J. Neurol. Sci. 12 (1985) 106-110
42. Dyment D.A., and Ebers G.C. Microsatellites and genome scans - a GAMES postscript. J. Neuroimmunol. 190 (2007) 5-7
43. Dyment D.A., Steckley J.L., Willer C.J., Armstrong H., Sadovnick A.D., Risch N., and Ebers G.C. No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian collaborative study. J. Neuroimmunol. 123 (2002) 193-198
44. Dyment D.A., Ebers G.C., and Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol. 3 (2004) 104-110
45. Dyment D.A., Herrera B.M., Cader M.Z., Willer C.J., Lincoln M.R., Sadovnick A.D., Risch N., and Ebers G.C. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 14 (2005) 2019-2026
46. Ebers G.C., and Sadovnick A.D. Association studies in multiple sclerosis. J. Neuroimmunol. 53 (1994) 117-122
47. Engell T., Raun N.E., Thomsen M., and Platz P. HLA and heterogeneity of multiple sclerosis. Neurology 32 (1982) 1043-1046
48. Evangelou N., Jackson M., Beeson D., and Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 67 (1999) 203-205
49. Falcone M., Rajan A.J., Bloom B.R., and Brosnan C.F. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J. Immunol. 160 (1998) 4822-4830
50. Fazekas F., Strasser-Fuchs S., Kollegger H., Berger T., Kristoferitsch W., Schmidt H., Enzinger C., Schiefermeier M., Schwarz C., Kornek B., Reindl M., Huber K., Grass R., Wimmer G., Vass K., Pfeiffer K.H., Hartung H.P., and Schmidt R. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 57 (2001) 853-857
51. Feakes R., Sawcer S., Broadley S., Coraddu F., Roxburgh R., Gray J., Clayton D., and Compston A. Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. J. Neuroimmunol. 105 (2000) 96-101
52. Fedetz M., Matesanz F., Pascual M., Martin J., Fernandez O., Guerrero M., and Alcina A. The -174/-597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis. J. Neurol. Sci. 190 (2001) 69-72
53. *0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J. Neurol. 251 (2004) 440-444
54. Ferri C., Sciacca F.L., Veglia F., Martinelli F., Comi G., Canal N., and Grimaldi L.M. APOE epsilon2-4 and -491 polymorphisms are not associated with MS. Neurology 53 (1999) 888-889
55. Ferri C., Sciacca F.L., Grimaldi L.E., Veglia F., Magnani G., Santuccio G., Comi G., Canal N., and Grimaldi L.M. Lack of association between IL-1A and IL-1B promoter polymorphisms and multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 69 (2000) 564-565
56. *0101 allele. Tissue Antigens 46 (1995) 333-336
57. Francis D.A., Thompson A.J., Brookes P., Davey N., Lechler R.I., McDonald W.I., and Batchelor J.R. Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ?. Hum. Immunol. 32 (1991) 119-124
58. Frei K., Fredrikson S., Fontana A., and Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J. Neuroimmunol. 31 (1991) 147-153
59. Fukazawa T., Yanagawa T., Kikuchi S., Yabe I., Sasaki H., Hamada T., Miyasaka K., Gomi K., and Tashiro K. CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J. Neurol. Sci. 171 (1999) 49-55
60. Gade-Andavolu R., Comings D.E., MacMurray J., Rostamkhani M., Cheng L.S., Tourtellotte W.W., and Cone L.A. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet. Med. 6 (2004) 126-131
61. Goris A., Maranian M., Walton A., Yeo T.W., Ban M., Gray J., Dubois B., Compston A., and Sawcer S. CD24 Ala/Val polymorphism and multiple sclerosis. J. Neuroimmunol. 175 (2006) 200-202
62. Green A.J., Barcellos L.F., Rimmler J.B., Garcia M.E., Caillier S., Lincoln R.R., Bucher P., Pericak-Vance M.A., Haines J.L., Hauser S.L., and Oksenberg J.R. Sequence variation in the transforming growth factor-beta1 (TGFB1) gene and multiple sclerosis susceptibility. J. Neuroimmunol. 116 (2001) 116-124
63. Greer J.M., and Pender M.P. The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76 (2005) 656-662
64. Gregersen J.W., Kranc K.R., Ke X., Svendsen P., Madsen L.S., Thomsen A.R., Cardon L.R., Bell J.I., and Fugger L. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 443 (2006) 574-577
65. Guerrero A.L., Laherran E., Gutierrez F., Martin-Polo J., Iglesias F., Alcazar C., Peralta J., and Rostami P. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol. Scand. 117 (2008) 21-25
66. Haase C.G., Schmidt S., and Faustmann P.M. Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci. Lett. 330 (2002) 293-295
67. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352 (2005) 997-1003
68. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E., Roxburgh R., Coraddu F., Smith S., and Compston D.A. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 72 (2002) 184-187
69. Hensiek A.E., Roxburgh R., Meranian M., Seaman S., Yeo T., Compston D.A., and Sawcer S.J. Osteopontin gene and clinical severity of multiple sclerosis. J. Neurol. 250 (2003) 943-947
70. Hensiek A.E., Seaman S.R., Barcellos L.F., Oturai A., Eraksoi M., Cocco E., Vecsei L., Stewart G., Dubois B., Bellman-Strobl J., Leone M., Andersen O., Bencsik K., Booth D., Celius E.G., Harbo H.F., Hauser S.L., Heard R., Hillert J., Myhr K.M., Marrosu M.G., Oksenberg J.R., Rajda C., Sawcer S.J., Sorensen P.S., Zipp F., and Compston D.A. Familial effects on the clinical course of multiple sclerosis. Neurology 68 (2007) 376-383
71. Hillert J., Gronning M., Nyland H., Link H., and Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 55 (1992) 887-890
72. Hogh P., Oturai A., Schreiber K., Blinkenberg M., Jorgensen O.S., Ryder L., Paulson O.B., Sorensen P.S., and Knudsen G.M. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult. Scler. 6 (2000) 226-230
73. Hooper-van Veen T., Schrijver H.M., Zwiers A., Crusius J.B., Knol D.L., Kalkers N.F., Laine M.L., Barkhof F., Pena A.S., Polman C.H., and Uitdehaag B.M. The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. Mult. Scler. 9 (2003) 535-539
74. Huang W.X., Huang P., Link H., and Hillert J. Cytokine analysis in multiple sclerosis by competitive RT-PCR: a decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression. Mult. Scler. 5 (1999) 342-348
75. Ignatius M.J., Gebicke-Harter P.J., Skene J.H., Schilling J.W., Weisgraber K.H., Mahley R.W., and Shooter E.M. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 1125-1129
76. Jansson M., Panoutsakopoulou V., Baker J., Klein L., and Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 168 (2002) 2096-2099
77. Jersild C., Svejgaard A., Fog T., and Ammitzboll T. HL-A antigens and diseases. I. Multiple sclerosis. Tissue Antigens 3 (1973) 243-250
78. Johns L.D., Flanders K.C., Ranges G.E., and Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol. 147 (1991) 1792-1796
79. Kamali-Sarvestani E., Nikseresht A., Aflaki E., Sarvari J., and Gharesi-Fard B. TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol. Scand. 115 (2007) 161-166
80. Kantarci O.H., Atkinson E.J., Hebrink D.D., McMurray C.T., and Weinshenker B.G. Association of a myeloperoxidase promoter polymorphism with multiple sclerosis. J. Neuroimmunol. 105 (2000) 189-194
81. Kantarci O.H., Atkinson E.J., Hebrink D.D., McMurray C.T., and Weinshenker B.G. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J. Neuroimmunol. 106 (2000) 220-227
82. Kantarci O.H., de Andrade M., and Weinshenker B.G. Identifying disease modifying genes in multiple sclerosis. J. Neuroimmunol. 123 (2002) 144-159
83. Kantarci O.H., Schaefer-Klein J.L., Hebrink D.D., Achenbach S.J., Atkinson E.J., McMurray C.T., and Weinshenker B.G. A population-based study of IL4 polymorphisms in multiple sclerosis. J. Neuroimmunol. 137 (2003) 134-139
84. Kantarci O.H., Hebrink D.D., Achenbach S.J., Pittock S.J., Altintas A., Schaefer-Klein J.L., Atkinson E.J., De Andrade M., McMurray C.T., Rodriguez M., and Weinshenker B.G. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 62 (2004) 811-814
85. Kantarci O.H., Morales Y., Ziemer P.A., Hebrink D.D., Mahad D.J., Atkinson E.J., Achenbach S.J., De Andrade M., Mack M., Ransohoff R.M., Lassmann H., Bruck W., Weinshenker B.G., and Lucchinetti C.F. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J. Neuroimmunol. 169 (2005) 137-143
86. Kantor R., Bakhanashvili M., and Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 61 (2003) 238-240
87. *1501 and disease modulation. J. Neuroimmunol. 128 (2002) 77-81
88. Koutsis G., Panas M., Karadima G., Mandellos D., Sfagos C., Potagas C., and Vassilopoulos D. APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score. J. Neurol. 254 (2007) 394-395
89. Kremenchutzky M., Cottrell D., Rice G., Hader W., Baskerville J., Koopman W., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 122 Pt 10 (1999) 1941-1950
90. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult. Scler. 4 (1998) 93-98
91. Link J., Soderstrom M., Olsson T., Hojeberg B., Ljungdahl A., and Link H. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann. Neurol. 36 (1994) 379-386
92. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., Slavin A.J., Old L., and Bernard C.C. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4 (1998) 78-83
93. Lundmark F., Salter H., and Hillert J. An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis. Mult. Scler. 13 (2007) 697-700
94. Luomala M., Lehtimaki T., Elovaara I., Wang X., Ukkonen M., Mattila K., Laippala P., Koivula T., and Hurme M. A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis. J. Neurol. Sci. 185 (2001) 123-127
95. Luomala M., Lehtimaki T., Huhtala H., Ukkonen M., Koivula T., Hurme M., and Elovaara I. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol. Scand. 108 (2003) 396-400
96. Madigand M., Oger J.J., Fauchet R., Sabouraud O., and Genetet B. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J. Neurol. Sci. 53 (1982) 519-529
97. Mann C.L., Davies M.B., Stevenson V.L., Leary S.M., Boggild M.D., Ko Ko C., Jones P.W., Fryer A.A., Strange R.C., Thompson A.J., and Hawkins C.P. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J. Neuroimmunol. 129 (2002) 197-204
98. Martin D., and Near S.L. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J. Neuroimmunol. 61 (1995) 241-245
99. Martin E.R., Lai E.H., Gilbert J.R., Rogala A.R., Afshari A.J., Riley J., Finch K.L., Stevens J.F., Livak K.J., Slotterbeck B.D., Slifer S.H., Warren L.L., Conneally P.M., Schmechel D.E., Purvis I., Pericak-Vance M.A., Roses A.D., and Vance J.M. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am. J. Hum. Genet. 67 (2000) 383-394
100. Martino G., Poliani P.L., Furlan R., Marconi P., Glorioso J.C., Adorini L., and Comi G. Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J. Neuroimmunol. 107 (2000) 184-190
101. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., and Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann. Neurol. 48 (2000) 211-219
102. Masterman T., Ligers A., Zhang Z., Hellgren D., Salter H., Anvret M., and Hillert J. CTLA4 dimorphisms and the multiple sclerosis phenotype. J. Neuroimmunol. 131 (2002) 208-212
103. Masterman T., Zhang Z., Hellgren D., Salter H., Anvret M., Lilius L., Lannfelt L., and Hillert J. APOE genotypes and disease severity in multiple sclerosis. Mult. Scler. 8 (2002) 98-103
104. Maurer M., Kruse N., Giess R., Kyriallis K., Toyka K.V., and Rieckmann P. Gene polymorphism at position -308 of the tumor necrosis factor alpha promotor is not associated with disease progression in multiple sclerosis patients. J. Neurol. 246 (1999) 949-954
105. Maurer M., Kruse N., Giess R., Toyka K.V., and Rieckmann P. Genetic variation at position -1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis. J. Neuroimmunol. 104 (2000) 98-100
106. Maurer M., Ponath A., Kruse N., and Rieckmann P. CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis. J. Neuroimmunol. 131 (2002) 213-215
107. McDonnell G.V., Kirk C.W., Middleton D., Droogan A.G., Hawkins S.A., Patterson C.C., and Graham C.A. Genetic association studies of tumour necrosis factor alpha and beta and tumour necrosis factor receptor 1 and 2 polymorphisms across the clinical spectrum of multiple sclerosis. J. Neurol. 246 (1999) 1051-1058
108. McDonnell G.V., Mawhinney H., Graham C.A., Hawkins S.A., and Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J. Neurol. Sci. 165 (1999) 77-83
109. McDonnell G.V., Kirk C.W., Hawkins S.A., and Graham C.A. An evaluation of interleukin genes fails to identify clear susceptibility loci for multiple sclerosis. J. Neurol. Sci. 176 (2000) 4-12
110. Mira M.T., Alcais A., Nguyen V.T., Moraes M.O., Di Flumeri C., Vu H.T., Mai C.P., Nguyen T.H., Nguyen N.B., Pham X.K., Sarno E.N., Alter A., Montpetit A., Moraes M.E., Moraes J.R., Dore C., Gallant C.J., Lepage P., Verner A., Van De Vosse E., Hudson T.J., Abel L., and Schurr E. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427 (2004) 636-640
111. Misu T., Onodera H., Fujihara K., Matsushima K., Yoshie O., Okita N., Takase S., and Itoyama Y. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J. Neuroimmunol. 114 (2001) 207-212
112. Mycko M., Kowalski W., Kwinkowski M., Buenafe A.C., Szymanska B., Tronczynska E., Plucienniczak A., and Selmaj K. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J. Neuroimmunol. 84 (1998) 198-206
113. Myhr K.M., Vagnes K.S., Maroy T.H., Aarseth J.H., Nyland H.I., and Vedeler C.A. Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J. Neurol. Sci. 202 (2002) 93-97
114. Nagra R.M., Becher B., Tourtellotte W.W., Antel J.P., Gold D., Paladino T., Smith R.A., Nelson J.R., and Reynolds W.F. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J. Neuroimmunol. 78 (1997) 97-107
115. Navikas V., Matusevicius D., Soderstrom M., Fredrikson S., Kivisakk P., Ljungdahl A., Hojeberg B., and Link H. Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J. Neuroimmunol. 64 (1996) 63-69
116. Nebert D.W. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur. J. Pharmacol. 410 (2000) 107-120
117. Nicoletti F., Patti F., DiMarco R., Zaccone P., Nicoletti A., Meroni P., and Reggio A. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 8 (1996) 395-400
118. Niino M., Kikuchi S., Fukazawa T., Yabe I., Sasaki H., and Tashiro K. Genetic polymorphisms of IL-1beta and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 118 (2001) 295-299
119. Niino M., Kikuchi S., Fukazawa T., Yabe I., and Tashiro K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 136 (2003) 125-129
120. Niino M., Kikuchi S., Fukazawa T., Yabe I., and Tashiro K. Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis. Mult. Scler. 9 (2003) 382-386
121. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
122. Olerup O., and Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38 (1991) 1-15
123. Olerup O., Hillert J., Fredrikson S., Olsson T., Kam-Hansen S., Moller E., Carlsson B., and Wallin J. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 7113-7117
124. Paty D.W., Dossetor J.B., Stiller C.R., Cousin H.K., Marchuk L., Furesz J., and Boucher D.W. HLA in multiple sclerosis. Relationship to measles antibody, mitogen responsiveness and clinical course. J. Neurol. Sci. 32 (1977) 371-379
125. Peltonen L. Old suspects found guilty-the first genome profile of multiple sclerosis. N. Engl. J. Med. 357 (2007) 927-929
126. Pickard C., Mann C., Sinnott P., Boggild M., Hawkins C., Strange R.C., Hutchinson I.V., Ollier W.E., and Donn R.P. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J. Neuroimmunol. 101 (1999) 207-210
127. Pina M.A., Ara J.R., Lasierra P., Modrego P.J., and Larrad L. Study of HLA as a predisposing factor and its possible influence on the outcome of multiple sclerosis in the sanitary district of Calatayud, northern Spain. Neuroepidemiology 18 (1999) 203-209
128. Pinholt M., Frederiksen J.L., Andersen P.S., and Christiansen M. Apo E in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis. Mult. Scler. 11 (2005) 511-515
129. Pirttila T., Haanpaa M., Mehta P.D., and Lehtimaki T. Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster. Acta Neurol. Scand. 102 (2000) 94-98
130. Poser S., Ritter G., Bauer H.J., Grosse-Wilde H., Kuwert E.K., and Raun N.E. HLA-antigens and the prognosis of multiple sclerosis. J. Neurol. 225 (1981) 219-221
131. Pulkkinen K., Luomala M., Kuusisto H., Lehtimaki T., Saarela M., Jalonen T.O., and Elovaara I. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol. Scand. 109 (2004) 342-347
132. Racke M.K., Dhib-Jalbut S., Cannella B., Albert P.S., Raine C.S., and McFarlin D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146 (1991) 3012-3017
133. Raknes G., Fernandes Filho J.A., Pandey J.P., Myhr K.M., Ulvestad E., Nyland H., and Vedeler C.A. IgG allotypes and subclasses in Norwegian patients with multiple sclerosis. J. Neurol. Sci. 175 (2000) 111-115
134. Ramagopalan S.V., Deluca G.C., Morrison K.M., Herrera B.M., Dyment D.A., Orton S., Bihoreau M.T., Degenhardt A., Pugliatti M., Sadovnick A.D., Sotgiu S., and Ebers G.C. No effect of APOE and PVRL2 on the clinical outcome of multiple sclerosis. J. Neuroimmunol. 186 (2007) 156-160
135. Ramagopalan S.V., Morris A.P., Dyment D.A., Herrera B.M., DeLuca G.C., Lincoln M.R., Orton S.M., Chao M.J., Sadovnick A.D., and Ebers G.C. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet. 3 (2007) 1607-1613
136. Ramsaransing G.S., Heersema D.J., and De Keyser J. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Eur. J. Neurol. 12 (2005) 514-518
137. Reekers P., Hommes O.R., Creemers-Molenaar J., Wijnings J., Kunst V.A., and Van Rood J.J. HLA-typing and lymphocyte population studies in patients with multiple sclerosis. J. Neurol. Sci. 33 (1977) 143-153
138. Risch N., and Zhang H. Extreme discordant sib pairs for mapping quantitative trait loci in humans. Science 268 (1995) 1584-1589
139. Ristic S., Lovrecic L., Starcevic-Cizmarevic N., Brajenovic-Milic B., Jazbec S.S., Barac-Latas V., Vejnovic D., Sepcic J., Kapovic M., and Peterlin B. No association of CCR5delta32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Mult. Scler. 12 (2006) 360-362
140. Ristic S., Lovrecic L., Starcevic-Cizmarevic N., Brajenovic-Milic B., Sega Jazbec S., Sepcic J., Kapovic M., and Peterlin B. Tumor necrosis factor-alpha-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Eur. Neurol. 57 (2007) 203-207
141. Rosche B., Cepok S., Stei S., Vogel F., Grummel V., Hoffmann S., Kroner A., Maurer M., Rieckmann P., Sommer N., and Hemmer B. The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MS. J. Neuroimmunol. 156 (2004) 171-177
142. Roxburgh R.H., Sawcer S., Maranian M., Seaman S., Hensiek A., Yeo T., Deans J., and Compston A. No evidence of a significant role for CTLA-4 in multiple sclerosis. J. Neuroimmunol. 171 (2006) 193-197
143. Runmarker B., and Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116 Pt 1 (1993) 117-134
144. Runmarker B., Martinsson T., Wahlstrom J., and Andersen O. HLA and prognosis in multiple sclerosis. J. Neurol. 241 (1994) 385-390
145. Salier J.P., Sesboue R., Martin-Mondiere C., Daveau M., Cesaro P., Cavelier B., Coquerel A., Legrand L., Goust J.M., and Degos J.D. Combined influences of Gm and HLA phenotypes upon multiple sclerosis susceptibility and severity. J. Clin. Invest. 78 (1986) 533-538
146. Santos M., do Carmo Costa M., Edite Rio M., Jose Sa M., Monteiro M., Valenca A., Sa A., Dinis J., Figueiredo J., Bigotte de Almeida L., Valongueiro A., Coelho I., Matama M.T., Pinto-Basto J., Sequeiros J., and Maciel P. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult. Scler. 10 (2004) 153-157
147. Savettieri G., Cittadella R., Valentino P., Manna I., Andreoli V., La Russa A., La Porta G., Ruscica F., Ragonese P., Pirritano D., Bonavita S., Tedeschi G., and Quattrone A. Lack of association between estrogen receptor 1 gene polymorphisms and multiple sclerosis in southern Italy in humans. Neurosci. Lett. 327 (2002) 115-118
148. Savettieri G., Andreoli V., Bonavita S., Cittadella R., Caltagirone C., Fazio M.C., Girlanda P., Le Pira F., Liguori M., Logroscino G., Lugaresi A., Nocentini U., Reggio A., Salemi G., Serra P., Tedeschi G., Toma L., Trojano M., Valentino P., and Quattrone A. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J. Neurol. 250 (2003) 1094-1098
149. Schmidt S., Barcellos L.F., DeSombre K., Rimmler J.B., Lincoln R.R., Bucher P., Saunders A.M., Lai E., Martin E.R., Vance J.M., Oksenberg J.R., Hauser S.L., Pericak-Vance M.A., and Haines J.L. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am. J. Hum. Genet. 70 (2002) 708-717
150. Schmidt S., Papassotiropoulos A., Sotgiu S., Kolsch H., Arru G., Fois M.L., Haase C.G., Schmitz S., Konig N., Harzheim M., Heun R., and Klockgether T. Investigation of a genetic variation of a variable number tandem repeat polymorphism of interleukin-6 gene in patients with multiple sclerosis. J. Neurol. 250 (2003) 607-611
151. Schmidt S., Pericak-Vance M.A., Sawcer S., Barcellos L.F., Hart J., Sims J., Prokop A.M., van der Walt J., DeLoa C., Lincoln R.R., Oksenberg J.R., Compston A., Hauser S.L., Haines J.L., and Gregory S.G. Allelic association of sequence variants in the herpes virus entry mediator-B gene (PVRL2) with the severity of multiple sclerosis. Genes Immun. 7 (2006) 384-392
152. *1501, CCR5 deletion mutation, apolipoprotein E). Mult. Scler. 8 (2002) 295-298
153. Schrijver H.M., Crusius J.B., Uitdehaag B.M., Garcia Gonzalez M.A., Kostense P.J., Polman C.H., and Pena A.S. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 52 (1999) 595-599
154. Sciacca F.L., Ferri C., Vandenbroeck K., Veglia F., Gobbi C., Martinelli F., Franciotta D., Zaffaroni M., Marrosu M., Martino G., Martinelli V., Comi G., Canal N., and Grimaldi L.M. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 52 (1999) 1896-1898
155. Sedano M.I., Calmarza P., Perez L., and Trejo J.M. No association of apolipoprotein E epsilon4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis. Mult. Scler. 12 (2006) 13-18
156. Sellebjerg F., Madsen H.O., Jensen C.V., Jensen J., and Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102 (2000) 98-106
157. Selmaj K., Raine C.S., and Cross A.H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30 (1991) 694-700
158. Sharief M.K., and Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325 (1991) 467-472
159. Silva A.M., Pereira C., Bettencourt A., Carvalho C., Couto A.R., Leite M.I., Marta M., Freijo M., Costa P.P., Mendonca D., Monteiro L., Armas J.B., and Martins B. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. J. Neurol. Sci. 258 (2007) 69-74
160. Silversides J.A., Heggarty S.V., McDonnell G.V., Hawkins S.A., and Graham C.A. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult. Scler. 10 (2004) 149-152
161. Siva A., Kesselring J., Thompson A.J., and European Committee for Treatment and Research in Multiple Sclerosis. Frontiers in multiple sclerosis (1999), Martin Dunitz, London pp. x, 281
162. Smestad C., Brynedal B., Jonasdottir G., Lorentzen A.R., Masterman T., Akesson E., Spurkland A., Lie B.A., Palmgren J., Celius E.G., Hillert J., and Harbo H.F. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur. J. Neurol. 14 (2007) 835-840
163. Soderstrom M., Hillert J., Link J., Navikas V., Fredrikson S., and Link H. Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Mult. Scler. 1 (1995) 173-180
164. Sotgiu S., Pugliatti M., Sanna A., Sotgiu A., Castiglia P., Solinas G., Dolei A., Serra C., Bonetti B., and Rosati G. Multiple sclerosis complexity in selected populations: the challenge of Sardinia, insular Italy. Eur. J. Neurol. 9 (2002) 329-341
165. Stendahl-Brodin L., Link H., Moller E., and Norrby E. Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF. Acta Neurol. Scand. 59 (1979) 297-308
166. Strunk T., Bubel S., Mascher B., Schlenke P., Kirchner H., and Wandinger K.P. Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients. Ann. Neurol. 47 (2000) 269-273
167. Suppiah V., Goris A., Alloza I., Heggarty S., Dubois B., Carton H., Antiguedad A., Mendibe M., McDonnell G., Droogan A., Hawkins S., Graham C., and Vandenbroeck K. Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations. Int. J. Immunogenet. 32 (2005) 383-388
168. Urcelay E., Santiago J.L., Mas A., Martinez A., de Las Heras V., Arroyo R., and de la Concha E.G. Role of interleukin 4 in Spanish multiple sclerosis patients. J. Neuroimmunol. 168 (2005) 164-167
169. van Boxel-Dezaire A.H., Hoff S.C., van Oosten B.W., Verweij C.L., Drager A.M., Ader H.J., van Houwelingen J.C., Barkhof F., Polman C.H., and Nagelkerken L. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45 (1999) 695-703
170. van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., Dascher C.C., Cheng T.Y., Sacks F.M., Illarionov P.A., Besra G.S., Kent S.C., Moody D.B., and Brenner M.B. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437 (2005) 906-910
171. Van Lambalgen R., Sanders E.A., and D'Amaro J. Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?. J. Neurol. Sci. 76 (1986) 13-21
172. van Veen T., Crusius J.B., van Winsen L., Xia B., Barkhof F., Salvador Pena A., Polman C.H., and Uitdehaag B.M. CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. J. Neuroimmunol. 140 (2003) 188-193
173. Vandenbroeck K., Martino G., Marrosu M., Consiglio A., Zaffaroni M., Vaccargiu S., Franciotta D., Ruggeri M., Comi G., and Grimaldi L.M. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J. Neuroimmunol. 76 (1997) 189-192
174. Vandenbroeck K., Fiten P., Ronsse I., Goris A., Porru I., Melis C., Rolesu M., Billiau A., Marrosu M.G., and Opdenakker G. High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease. Genes Immun 1 (2000) 460-463
175. Villoslada P., Barcellos L.F., Rio J., Begovich A.B., Tintore M., Sastre-Garriga J., Baranzini S.E., Casquero P., Hauser S.L., Montalban X., and Oksenberg J.R. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J. Neuroimmunol. 130 (2002) 194-201
176. Vogt M.H., Lopatinskaya L., Smits M., Polman C.H., and Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann. Neurol. 53 (2003) 819-822
177. Weatherby S.J., Mann C.L., Davies M.B., Carthy D., Fryer A.A., Boggild M.D., Young C., Strange R.C., Ollier W., and Hawkins C.P. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult. Scler. 6 (2000) 32-36
178. Weatherby S.J., Mann C.L., Fryer A.A., Strange R.C., Hawkins C.P., Stevenson V.L., Leary S.M., and Thompson A.J. No association between the APOE epsilon4 allele and outcome and susceptibility in primary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 68 (2000) 532
179. Weatherby S.J., Thomson W., Pepper L., Donn R., Worthington J., Mann C.L., Davies M.B., Fryer A.A., Boggild M.D., Young C.A., Jones P.W., Strange R.C., Ollier W.E., and Hawkins C.P. HLA-DRB1 and disease outcome in multiple sclerosis. J. Neurol. 248 (2001) 304-310
180. Weinshenker B.G. The natural history of multiple sclerosis. Neurol. Clin. 13 (1995) 119-146
181. Weinshenker B.G., Rice G.P., Noseworthy J.H., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 114 Pt 2 (1991) 1045-1056
182. Weinshenker B.G., Wingerchuk D.M., Liu Q., Bissonet A.S., Schaid D.J., and Sommer S.S. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 49 (1997) 378-385
183. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., and Rodriguez M. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 51 (1998) 742-747
184. Weinshenker B.G., Hebrink D., Kantarci O.H., Schaefer-Klein J., Atkinson E., Schaid D., and McMurray C.M. Genetic variation in the transforming growth factor beta1 gene in multiple sclerosis. J. Neuroimmunol. 120 (2001) 138-145
185. Zakrzewska-Pniewska B., Styczynska M., Podlecka A., Samocka R., Peplonska B., Barcikowska M., and Kwiecinski H. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult. Scler. 10 (2004) 266-271
186. Zang Y.C., Samanta A.K., Halder J.B., Hong J., Tejada-Simon M.V., Rivera V.M., and Zhang J.Z. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain 123 Pt 9 (2000) 1874-1882
187. Zhou Q., Rammohan K., Lin S., Robinson N., Li O., Liu X., Bai X.F., Yin L., Scarberry B., Du P., You M., Guan K., Zheng P., and Liu Y. CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15041-15046
188. Zwemmer J.N., van Veen T., van Winsen L., van Kamp G.J., Barkhof F., Polman C.H., and Uitdehaag B.M. No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult. Scler. 10 (2004) 272-277